Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.


Opinion for Johnson & Johnson (JNJ-N)

Signal Price Bias Subject Owned

The US$ has weakened against all currencies this year, and for US multinationals that is going to be a nice tailwind for them. About 50% of revenues come from North America. About 45% of revenues come from the pharmaceutical division, and then they have the medical devices and the consumer products division. Their Pharma division has really started to show nice organic growth, and investments in their pipeline are paying off. Going forward, management has indicated they expect to file 10 new products by 2019 with revenue potential of $1 billion, so she sees good visibility in the pipeline going forward. Organic growth is picking up. They increase the dividend every year and have done so for the last 55 years. Dividend yield of 2.5%. (Analysts’ price target is $142.)

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management

No Comments.

You must be logged in to comment.